


PRODUCT INFORMATION



Meloxicam

Item No. 14906

CAS Registry No.: 71125-38-7
Formal Name: 4-hydroxy-2-methyl-N-(5-methyl-2-thiazolyl)-1,1-dioxide-2H-1,2-benzothiazine-3-carboxamide
Synonym: UH-AC 62XX
MF: C₁₄H₁₃N₃O₄S₂
FW: 351.4
Purity: ≥95%
UV/Vis.: λ_{max}: 253, 348, 355 nm
Supplied as: A crystalline solid
Storage: -20°C
Stability: ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

Meloxicam is supplied as a crystalline solid. A stock solution may be made by dissolving the meloxicam in the solvent of choice. Meloxicam is soluble in organic solvents such as DMSO and dimethyl formamide, which should be purged with an inert gas. The solubility of meloxicam in these solvents is approximately 20 mg/ml.

Meloxicam is sparingly soluble in aqueous buffers. For maximum solubility in aqueous buffers, meloxicam should first be dissolved in DMSO and then diluted with the aqueous buffer of choice. Meloxicam has a solubility of approximately 0.5 mg/ml in a 1:1 solution of DMSO:PBS (pH 7.2) using this method. We do not recommend storing the aqueous solution for more than one day.

Description

Meloxicam is a selective inhibitor of COX-2 (IC₅₀s = 11.8 and 143 μM for COX-2 and COX-1, respectively, in an enzyme activity assay) and a non-steroidal anti-inflammatory drug (NSAID).¹ Meloxicam (0.03%) reduces croton oil-induced increases in TNF-α and IL-1β mRNA levels and increases IL-10 mRNA levels in cornea in a rabbit model of acute ocular inflammation.² It inhibits pleural plasma exudation in a carrageenan-induced rat model of pleurisy when administered at a dose of 3 mg/kg.¹ In a canine model of unilateral osteoarthritis of the right stifle joint, meloxicam reduces prostaglandin E₂ (PGE₂) levels in plasma and right stifle joint synovial fluid when administered at a dose of 0.2 mg/kg.³ Formulations containing meloxicam have been used in the treatment of osteoarthritis and rheumatoid arthritis.

References

1. Ogino, K., Hatanaka, K., Kawamura, M., *et al.* Evaluation of pharmacological profile of meloxicam as an anti-inflammatory agent, with particular reference to its relative selectivity for cyclooxygenase-2 over cyclooxygenase-1. *Pharmacology* **55**(1), 44-53 (1997).
2. Cruz, R., Quintana-Hau, J.D., González, J.R., *et al.* Effects of an ophthalmic formulation of meloxicam on COX-2 expression, PGE₂ release, and cytokine expression in a model of acute ocular inflammation. *Br. J. Ophthalmol.* **92**(1), 120-125 (2008).
3. Jones, C.J., Streppa, H.K., Harmon, B.G., *et al.* *In vivo* effects of meloxicam and aspirin on blood, gastric mucosal, and synovial fluid prostanoid synthesis in dogs. *Am. J. Vet. Res.* **63**(11), 1527-1531 (2002).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 11/08/2022

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897
[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM